Acquisition of an India-based operation and expansion of drug discovery support through genetic analysis services
First written in FY2018. 8 of 14 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「The company is also pursuing personalized medicine. Its group company REPROCELL Europe Ltd. successfully developed Pharmacology-AI, a machine-learning platform specializing in personalized medicine, jointly with IBM Research and the UK's STFC Hartree Centre.」
The company has reaffirmed its policy of expanding personalized medicine and drug discovery support by leveraging its global bases, including India, and genetic analysis and clinical testing services. - FY2023-Q3RestatedAnnual report
「The medical business is also focusing on contract clinical testing services. In Japan, these include PCR testing for the novel coronavirus and HLA-related testing associated with organ transplantation, while in India the company mainly provides cancer companion diagnostic services. It will continue expanding the business by adding new test items.」
The company has reaffirmed its policy of expanding its clinical testing business, including cancer companion diagnostic services using the Indian base's next-generation genomic analysis technology. - FY2023-Q2RestatedAnnual report
「The medical business is also focusing on contract clinical testing services. In Japan, these include PCR testing for the novel coronavirus and HLA-related testing associated with organ transplantation, while in India the company mainly provides cancer companion diagnostic services. It will continue expanding the business by adding new test items.」
The company has reaffirmed its policy of expanding its clinical testing business, including cancer companion diagnostic services using the Indian base's next-generation genomic analysis technology. - FY2023-Q1RestatedAnnual report
「The medical business is also focusing on contract clinical testing services. In Japan, these include PCR testing for the novel coronavirus and HLA-related testing associated with organ transplantation, while in India the company mainly provides cancer companion diagnostic services. It will continue expanding the business by adding new test items.」
The company has reaffirmed its policy of expanding its clinical testing business, including cancer companion diagnostic services using the Indian base's next-generation genomic analysis technology. - FY2022-Q3RestatedAnnual report
「In 2021, the Indian subsidiary also launched non-invasive prenatal testing, which examines fetal chromosomal abnormalities with high accuracy using maternal blood, and a cancer companion diagnostic service that examines cancer mutations and provides treatment optimized for each patient. The company will continue expanding its clinical testing business by applying the next-generation genomic analysis technology held by the Indian subsidiary.」
The company has reaffirmed its policy of offering non-invasive prenatal testing and cancer companion diagnostic services using the Indian base's next-generation genomic analysis technology. - FY2022-Q1AdvancedAnnual report
「In April 2021, the company also launched a companion diagnostic service for cancer. It will continue expanding its clinical testing business by applying the next-generation genomic analysis technology held by the Indian subsidiary.」
In April 2021, the Indian base launched a companion diagnostic service for cancer as part of its next-generation genomic analysis business and expanded its application to clinical testing. - FY2021AdvancedAnnual report
「In March 2021, the Indian subsidiary also launched a new non-invasive prenatal testing service. The test examines fetal chromosomal abnormalities with high accuracy using a maternal blood sample.」
The Indian base launched a new non-invasive prenatal testing service using maternal blood as part of its genetic analysis and next-generation sequencing business. - FY2020RestatedAnnual report
「In June 2019, the company established Fox Chase Bioserve Pvt. Ltd., a joint venture with Kamineni Life Sciences Pvt. Ltd., one of India's major hospital groups, through Biorepository LLC.」
The company has reaffirmed the framework for business expansion through its Indian base, the joint venture with the Kamineni hospital group and biological specimen banking. - FY2020-Q3RestatedAnnual report
「The company also held an opening ceremony for a new facility of its consolidated subsidiary Fox Chase Bioserve Pvt. Ltd. in India. Going forward, it will work with the Kamineni hospital group to establish a new human biological tissue banking operation in India. The company will market these biological specimens primarily to pharmaceutical companies in Japan, the United States and Europe.」
The company has reaffirmed its policy of advancing the new facility in India, biological tissue banking with the Kamineni hospital group and sales to pharmaceutical companies and other customers in Japan, the United States and Europe. - FY2020-Q2AdvancedAnnual report
「The company also held an opening ceremony for a new facility of its consolidated subsidiary Fox Chase Bioserve Pvt. Ltd. in India. Going forward, it will work with the Kamineni hospital group to establish a new human biological tissue banking operation in India. The company will market these biological specimens primarily to pharmaceutical companies in Japan, the United States and Europe.」
The Indian subsidiary opened a new facility and progressed to the stage of developing human biological tissue banking in cooperation with the Kamineni hospital group and selling the specimens to pharmaceutical companies and other customers in Japan, the United States and Europe. - FY2019-Q3RestatedAnnual report
「The company will also expand the contract next-generation sequencing business operated by Bioserve Biotechnologies India Pvt. Ltd., acquired in April 2018, as a new business area for the group. Next-generation sequencing is a new technology that enables large-scale, rapid DNA analysis, and the company will pursue its application to genetic analysis of the disease-model cells described above and other areas.」
The company has reaffirmed its policy of expanding the Indian subsidiary's contract next-generation sequencing business as a new business area and applying it to areas including genetic analysis of disease-model cells. - FY2019-Q2AdvancedAnnual report
「The company will also expand the contract next-generation sequencing business operated by Bioserve Biotechnologies India Pvt. Ltd., acquired in April 2018, as a new business area for the group. Next-generation sequencing is a new technology that enables large-scale, rapid DNA analysis, and the company will pursue its application to genetic analysis of the disease-model cells described above and other areas.」
The company announced a policy of expanding the Indian subsidiary's contract next-generation sequencing business as a new business area and pursuing applications including genetic analysis of disease-model cells. - FY2019-Q1AdvancedAnnual report
「During the first quarter of the fiscal year, the company made Bioserve Biotechnologies India Pvt. Ltd., which provides genetic analysis services in India, a subsidiary. Hereinafter, Bioserve Biotechnologies India Pvt. Ltd. is referred to as REPROCELL India. REPROCELL India currently focuses primarily on genetic analysis services. These are new services and technologies for the group, and the company will further expand the business through synergies with its existing businesses.」
Following the acquisition of the Indian company, the company moved to the stage of actually rolling out genetic analysis services and expanding the business through synergies with its existing drug discovery support using iPS cells and human cells. - FY2018First statedAnnual report
「Through this acquisition of shares, our Group will expand its global operations into India, provide higher-value-added drug discovery support services and accelerate our business.」
Bioserve Biotechnologies India Pvt. Ltd. was acquired on 26 April 2018 and made a subsidiary with a 98.28% voting interest. The company identified the technological synergies between genetic analysis services and its existing drug discovery support using iPS cells and human cells as a new business opportunity.